The FcγRIIIA (CD16) L48-H/R Polymorphism Enhances NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity by...

Area of Science:

• Immunology
• Cell Biology
• Cancer Research

Background:

• Monoclonal antibody therapies often rely on natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC).
• The FcγRIIIa (CD16) receptor on NK cells binds antibody Fc domains to initiate ADCC.
• The common CD16 F158-V polymorphism enhances ADCC, but other variants are less understood.

Purpose of the Study:

• To investigate the functional impact of CD16 L48-H and L48-R variants on NK cell-mediated ADCC.
• To compare the efficacy of CD16 48-H and 48-L variants in killing tumor cells.

Main Methods:

• In vitro assessment of ADCC responses using primary NK cells and NK-92 cell lines.
• Analysis of NK cell interactions with target cells, including synapse formation, calcium signaling, and cytolytic vesicle polarization.
• Evaluation of serial killing capacity.

Main Results:

• CD16 L48-H and L48-R variants significantly enhanced in vitro ADCC responses.
• NK cells expressing CD16 48-H exhibited faster killing and disengagement from target cells compared to CD16 48-L.
• CD16 48-H promoted a more compact immunologic synapse, robust calcium signaling, and quicker cytolytic vesicle polarization.

Conclusions:

• The CD16 L48-H/R polymorphisms enhance NK cell-mediated ADCC by improving cytolytic signaling and target cell disengagement.
• These variants facilitate efficient serial killing of tumor cells.
• The L48-H/R polymorphism may improve patient responses to cancer antibody therapies and enhance adoptive NK cell therapies.